tetano
Editor, Senior Moderator
Vaccine. 2010 Apr 19. [Epub ahead of print]
The immunogenicity of intradermal influenza vaccination in COPD patients.
Chuaychoo B, Wongsurakiat P, Nana A, Kositanont U, Maranetra KN.
Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital, Mahidol University, 2 Pranok Road, BangkokNoi, Bangkok 10700, Thailand.
Abstract
We evaluated the immunogenicity of a reduced-dose intradermal trivalent, inactivated, split-virion seasonal influenza vaccine compared to that of a conventional intramuscular vaccination in chronic obstructive pulmonary disease (COPD) patients. One hundred and fifty-six COPD patients randomly received either 0.2ml (6mug hemagglutinin (HA) per strain) split into two-site intradermal (ID) injections or a single 0.5ml (15mug HA per strain) intramuscular (IM) injection. Geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates at 4 weeks post-vaccination in the ID group were less than those in the IM group. Only the seroconversion factor to influenza B in the ID group was statistically less than in the IM group (18.8 in the ID group, n=81 versus 37.3 in the IM group, n=75, p=0.045). Nevertheless, each strain of the ID vaccination met all the Committee for Proprietary Medicinal Products (CPMP) criteria. Seroprotection rates were above 60% throughout the year in influenza A (H3N2), for at least 6 months in influenza A (H1N1) and at least 4 weeks in influenza B in both ID and IM groups. The reduced-dose intradermal vaccination may be considered for use in COPD patients in a vaccine shortage situation. Copyright ? 2010. Published by Elsevier Ltd.
PMID: 20412877 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20412877
The immunogenicity of intradermal influenza vaccination in COPD patients.
Chuaychoo B, Wongsurakiat P, Nana A, Kositanont U, Maranetra KN.
Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital, Mahidol University, 2 Pranok Road, BangkokNoi, Bangkok 10700, Thailand.
Abstract
We evaluated the immunogenicity of a reduced-dose intradermal trivalent, inactivated, split-virion seasonal influenza vaccine compared to that of a conventional intramuscular vaccination in chronic obstructive pulmonary disease (COPD) patients. One hundred and fifty-six COPD patients randomly received either 0.2ml (6mug hemagglutinin (HA) per strain) split into two-site intradermal (ID) injections or a single 0.5ml (15mug HA per strain) intramuscular (IM) injection. Geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates at 4 weeks post-vaccination in the ID group were less than those in the IM group. Only the seroconversion factor to influenza B in the ID group was statistically less than in the IM group (18.8 in the ID group, n=81 versus 37.3 in the IM group, n=75, p=0.045). Nevertheless, each strain of the ID vaccination met all the Committee for Proprietary Medicinal Products (CPMP) criteria. Seroprotection rates were above 60% throughout the year in influenza A (H3N2), for at least 6 months in influenza A (H1N1) and at least 4 weeks in influenza B in both ID and IM groups. The reduced-dose intradermal vaccination may be considered for use in COPD patients in a vaccine shortage situation. Copyright ? 2010. Published by Elsevier Ltd.
PMID: 20412877 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20412877